VivoSeq
Other

Omalizumab

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Omalizumab is an early-stage landscape with 0 programs across 4 companies. The most active players are Novartis, Roche, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalT

Taizhou Mabtech Pharmaceutical Co.,Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed14 · 70%
Active, not recruiting2 · 10%
Recruiting2 · 10%
Unknown status1 · 5%
Terminated1 · 5%

Clinical Trials

Trial Activity

20 trials

Omalizumab Before Onset of Exacerbations
Recruiting·—·Phase 2·NCT05332067·300 enrolled
Omalizumab Weight-Based Dosing Efficacy Trial
Recruiting·MMassachusetts General Hospital·Phase 2·NCT06943534·30 enrolled
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT06042478·470 enrolled
Omalizumab to Accelerate a Symptom-driven Multi-food OIT
Active, not recruiting·—·Phase 2·NCT04045301·90 enrolled
Omalizumab for Lupus
Completed·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 1·NCT01716312·17 enrolled
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
Completed·JJohns Hopkins University·Phase 2·NCT01003301·19 enrolled
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
Completed·JJohns Hopkins University·Phase 4·NCT02023151·17 enrolled
To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Completed·CCelltrion·Phase 1·NCT04018313·176 enrolled
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
Completed·Roche logoRoche·Phase 4·NCT01125748·176 enrolled
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01430403·478 enrolled
Omalizumab to Treat Hyper-IgE (Job's) Syndrome
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00260702·1 enrolled
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Completed·Sanofi logoSanofi·Phase 4·NCT04998604·360 enrolled
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
Completed·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 1·NCT04778137·114 enrolled
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children
Completed·Novartis logoNovartis·Phase 3·NCT01328886·38 enrolled
The Efficacy of Preseasonal Omalizumab Treatment
Completed·—·N/A·NCT04489121·31 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)